Filing Summary
Entity and period: The supplied filing is a Form 10-Q for Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.), for the quarter and nine months ended December 31, 2015. Financial amounts below are in U.S. dollars; the statements are presented in thousands. The company develops and markets dermatology and advanced tissue-care products, including products based on its Microcyn technology.
Financial performance
| Metric | Quarter ended Dec. 31, 2015 | Quarter ended Dec. 31, 2014 | Nine months ended Dec. 31, 2015 | Nine months ended Dec. 31, 2014 |
|---|---|---|---|---|
| Revenue | $3.820 million | $3.218 million | $11.554 million | $9.874 million |
| Gross profit / margin | $1.520 million / 40% | $1.656 million / 51% | $5.483 million / 47% | $5.294 million / 54% |
| Operating loss | $3.124 million | $1.949 million | $7.293 million | $5.007 million |
| Net loss | $3.149 million | $5.914 million | $7.252 million | $6.702 million |
| Basic and diluted loss per share | $0.19 | $0.69 | $0.45 | $0.79 |
- Revenue mix and change: Quarterly product revenue rose 40% to $3.473 million, while licensing fees and royalties fell 78% to $120,000; service revenue was $227,000. For the nine months, product revenue increased 47% to $9.793 million, licensing fees and royalties declined 65% to $906,000, and service revenue increased to $855,000.
- Drivers and margins: Management attributed product growth to U.S. dermatology launches and expansion of distribution, including in Latin America and Europe/other regions. Lower license revenue reflected reduced amortization of Sanfer upfront payments and the termination of the Innovacyn agreement. Quarterly gross margin fell mainly with lower license revenue and product mix; nine-month product gross margin improved to 45% from 38%, but total gross margin declined as license revenue decreased.
- Expenses and unusual items: Quarterly SG&A rose 28% to $4.158 million, primarily from sales and marketing, the dermatology sales force and product launches; R&D rose 32% to $486,000. For the nine months, SG&A rose 25% to $11.411 million and R&D rose 18% to $1.365 million. The prior-year quarter included a $4.650 million Ruthigen investment impairment, partly offset by a $679,000 derivative-liability fair-value gain. The nine-month prior-year comparison also included a $2.998 million derivative gain.
- Cash flow: Nine-month operating cash outflow was $7.024 million, compared with $4.064 million in the prior-year period. Investing cash inflow was $4.180 million, primarily from selling the remaining Ruthigen shares for $4.538 million, partially offset by equipment purchases. Financing cash inflow was $2.876 million, mainly from ATM stock sales. Cash decreased $23,000 from March 31, 2015 to $6.113 million.
- Liquidity and debt: At December 31, 2015, working capital was $8.346 million, current assets $11.139 million, and current liabilities $2.793 million. The balance sheet reported no current portion of long-term debt and no other long-term debt line item; the company paid $87,000 of debt principal during the nine months. Management stated it expects continuing losses and may need additional capital. The filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook and risks
- Compared with the prior-year quarter, revenue increased but gross margin narrowed and operating loss widened. The smaller reported quarterly net loss principally reflects the prior-year impairment charge, not an improvement in operating performance. For the nine months, net loss increased by $550,000.
- Management expected SG&A to remain within the current period’s range over the next several quarters. It gave no specific revenue or earnings guidance. U.S. pivotal trials to pursue Microcyn as a drug were to be delayed until a strategic partner or additional funding could be obtained.
- The company sold $2.949 million of net ATM equity proceeds during the nine months and, after quarter-end, sold additional shares for $202,000 net proceeds. Common shares outstanding increased from 15.045 million at March 31, 2015 to 17.342 million at December 31, 2015; the filing also reports 17,519,295 shares outstanding as of February 10, 2016.
- Risks include the need for additional financing, continued losses, uncertain commercialization and regulatory progress, competition, foreign-currency exposure, and customer concentration. One customer accounted for 35% of nine-month revenue; at quarter-end, five customers represented 85% of net receivables in aggregate. Management reported no material change to previously disclosed risk factors, no material change in internal control over financial reporting, and effective disclosure controls as of December 31, 2015.
- Other disclosed exposures include potential severance payments of $1.097 million under executive employment agreements if triggered. Management characterized ordinary-course legal matters as currently insignificant but noted litigation could adversely affect the business.
Key facts for investors to verify
- Confirm that this Oculus Innovative Sciences filing is the intended filing for the requested Sonoma Pharmaceuticals summary.
- Assess cash runway and financing needs against the going-concern warning, operating cash burn, and subsequent ATM share sales; the filing does not provide a clear cash-runway estimate.
- Track whether product growth and U.S. dermatology launches can offset declining licensing revenue and improve total gross margin.
- Review customer concentration, receivable collectability and foreign-exchange effects, including peso and euro declines cited by management.
- Verify the timing and funding of planned clinical trials and any required regulatory steps; the filing reports 510(k) clearances for certain products but not approval to market Microcyn as a U.S. drug.